In its report, titled "Alpha-2 Antiplasmin Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," Transparency Market Research (TMR) provides a professional and in-depth study on the prevailing dynamics of the global alpha-2 antiplasmin market and insights into factors that will impact the market's growth trajectory between 2013 and 2019. The report provides a comprehensive overview of the market covering the definition of key products, classification based on various parameters, and development status of key regional markets.
Alpha-2 antiplasmin, also known as a plasmin inhibitor, is a type of glycoprotein, which is synthesized by the kidneys, liver, and other tissues of the body. It belongs to the serpin superfamily, which functions as the primary inhibitor of serine protease plasmin. Deficiency of Alpha 2 antiplasmin may cause bleeding disorders, since it increases fibrionolysis. It is responsible for inhibiting fibrinolysis and the degradation of fibrin clots. Congenital deficiency of Alpha 2 antiplasmin can also lead to internal hemorrhage. Alpha-2 antiplasmin is available in two distinct forms: non-plasminogen binding and plasminogen binding.
The mounting pressure for cost containment in major industrialized nations and the evolution of the latest technologies are anticipated to dramatically change coagulation testing practices in the next five years. New sensitive and specific markets for hemostasis will increasingly demand automated instrumentation. Influenced by the prevailing trends, it is very likely that Alpha-2 antiplasmin will become more standardized and offer better opportunities for quality control products and services. Additionally, the continuing contraction of hospital systems and the launch of the latest technological advances will facilitate decentralizing Alpha-2 antiplasmin testing and bring it closer to patients, thereby creating lucrative opportunities for the enterprises operating in the market to capitalize on.
The report presents a detailed overview of the global market for Alpha-2 antiplasmin across Asia Pacific, Europe, North America, and Rest of the World. Of these, North America emerged as the most lucrative market for Alpha-2 antiplasmin, since the region witnesses a rising number of metabolic syndrome cases. Research has demonstrated that the presence of Alpha-2 antiplasmin in excess is associated with cardiovascular diseases and metabolic syndrome. Deficiency of Alpha-2 antiplasmin may cause the development of atherosclerosis. According to a report published by the American Heart Association, over 35% of adults in the U.S. suffer from metabolic syndrome. This aids the expansion of the Alpha-2 antiplasmin market in North America. The market also sees favorable growth potential in Asia Pacific and Europe, since these regions witness an increasing incidence of cardiovascular diseases.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453